Immunoglobulin Market Size, Share & Industry Analysis, By Route of Administration (Intravenous and Subcutaneous), By Indication (Primary Immunodeficiency, Secondary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barré Syndrome, Immune Thrombocytopenic Purpura, Multifocal Motor Neuropathy, and Others), By Form (Liquid and Lyophilized), By End-user (Hospitals, Clinics, and Homecare), and Regional Forecast, 2024-2032

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2022

Growth Rate

CAGR of 9.3% from 2024-2032

Unit

Value (USD billion)

Segmentation

By Route of Administration

• Intravenous
• Subcutaneous

By Indication

• Primary Immunodeficiency (PI)
• Secondary Immunodeficiency (SID)
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Guillain Barré Syndrome
• Immune Thrombocytopenic Purpura (ITP)
• Multifocal Motor Neuropathy (MMN)
• Others

By Form

• Liquid
• Lyophilized

By End-user

• Hospitals
• Clinics
• Homecare

By Geography

• North America (By Route of Administration, By Indication, By Form, By End-user, and By Country)
• U.S.
• Canada
• Europe (By Route of Administration, By Indication, By Form, By End-user, and By Country/Sub-region)
• U.K.
• Germany
• France
• Italy
• Spain
• Scandinavia
• Rest of Europe
• Asia Pacific (By Route of Administration, Bu Indication, By Form, By End-user, and By Country/Sub-region)
• China
• Japan
• India
• Australia
• Southeast Asia
• Rest of Asia Pacific
• Latin America (By Route of Administration, By Indication, By Form, By End-user, and By Country/Sub-region)
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa (By Route of Administration, Bu Indication, By Form, By End-user, and By Country/Sub-region)
• GCC
• South Africa
• Rest of Middle East & Africa